SynAct Pharma Receives US Patent Allowance for Resomelagon Tablet Formulation

• SynAct Pharma received a U.S. patent allowance covering the immediate-release oral formulation of resomelagon, its lead drug candidate in clinical testing.
• The formulation patent would add protection through June 2042; an existing crystal-form patent extends through July 2, 2044.
• Resomelagon is being developed as a once-daily oral selective melanocortin agonist for rheumatoid arthritis and host-directed therapy in viral infections.
• Clinical development includes combination treatment with first-line methotrexate for rheumatoid arthritis and evaluation against excessive inflammation in severe viral disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611130220ACCESSWRNAPR_____1250964) on November 13, 2026, and is solely responsible for the information contained therein.